AP2016009662A0 - Combination of taurine and racemethionine for treatment of liver diseases - Google Patents
Combination of taurine and racemethionine for treatment of liver diseasesInfo
- Publication number
- AP2016009662A0 AP2016009662A0 AP2016009662A AP2016009662A AP2016009662A0 AP 2016009662 A0 AP2016009662 A0 AP 2016009662A0 AP 2016009662 A AP2016009662 A AP 2016009662A AP 2016009662 A AP2016009662 A AP 2016009662A AP 2016009662 A0 AP2016009662 A0 AP 2016009662A0
- Authority
- AP
- ARIPO
- Prior art keywords
- racemethionine
- taurine
- treatment
- combination
- liver diseases
- Prior art date
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title 2
- 208000019423 liver disease Diseases 0.000 title 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 title 1
- 229940080308 racemethionine Drugs 0.000 title 1
- 229960003080 taurine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1668MU2014 | 2014-05-19 | ||
| PCT/IN2014/000510 WO2015177805A1 (en) | 2014-05-19 | 2014-08-01 | Combination of taurine and racemethionine for treatment of liver diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2016009662A0 true AP2016009662A0 (en) | 2016-12-31 |
Family
ID=51903973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2016009662A AP2016009662A0 (en) | 2014-05-19 | 2014-08-01 | Combination of taurine and racemethionine for treatment of liver diseases |
Country Status (3)
| Country | Link |
|---|---|
| AP (1) | AP2016009662A0 (en) |
| EA (1) | EA201691599A1 (en) |
| WO (1) | WO2015177805A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817695A (en) | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| EP1648472A2 (en) * | 2003-07-01 | 2006-04-26 | Ranbaxy Laboratories, Ltd. | Stable oral compositions of azithromycin monohydrate |
| KR100549697B1 (en) | 2004-12-10 | 2006-02-07 | 김세규 | Amino acid supplement food |
| WO2011045810A1 (en) * | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
| WO2013124860A1 (en) * | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Potent revital formulation |
-
2014
- 2014-08-01 AP AP2016009662A patent/AP2016009662A0/en unknown
- 2014-08-01 EA EA201691599A patent/EA201691599A1/en unknown
- 2014-08-01 WO PCT/IN2014/000510 patent/WO2015177805A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EA201691599A1 (en) | 2016-11-30 |
| WO2015177805A1 (en) | 2015-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252839A0 (en) | Treatment of pemphigus | |
| SG11201701723XA (en) | Methods of treating liver disease | |
| PT3212233T (en) | Combination therapy for treatment of disease | |
| HK1258062A1 (en) | Methods of administering elagolix | |
| GB201701673D0 (en) | Methods of well treatment | |
| HUE047952T2 (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| HK1232220A1 (en) | Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases 5- | |
| HK1258994A1 (en) | Methods for treatment of diseases | |
| HK1244711A1 (en) | Treatment of hmgb1-mediated inflammation | |
| EP3134108A4 (en) | Agents and methods of treatment | |
| GB201416832D0 (en) | Methods of treatment | |
| HK1249866A1 (en) | Methods of treatment with taselisib | |
| IL259710A (en) | Compositions and methods of treatment for mvid and related diseases | |
| GB201408297D0 (en) | Treatment of cancer | |
| HK1246271A1 (en) | Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases | |
| HK1244782A1 (en) | Compositions and methods for treating diseases and conditions | |
| HK1243937A1 (en) | Methods of treating diseases | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201417248D0 (en) | Compostion and methods of treatment | |
| GB201622116D0 (en) | Treatment of liver disease | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201417456D0 (en) | Treatment of cancer | |
| AP2016009662A0 (en) | Combination of taurine and racemethionine for treatment of liver diseases | |
| GB201613350D0 (en) | Treatment of hyperpigmentation | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer |